

The civic association Dom Svetla Slovensko is a non-governmental, non-profit organization whose main goal is to eliminate the stigmatization of people living with HIV in society, to advocate and promote their human rights and to prevent the spread of HIV/AIDS and other sexually transmitted diseases. The association is guided by the principles of non-partisanship, independence, transparency and non-discrimination in the pursuit of its objectives. As a civil association, Dom Svetla Slovensko has been actively involved in testing for sexual and blood-borne infections since 2017. They have their own testing Check Point where they offer anonymous and free testing for HIV, syphilis and hepatitis B and C. They are also engaged in awareness, prevention and education activities.
Dom Svetla Slovensko are regular participants in Slovak PRIDEs, and they are also involved in testing in marginalized and socially excluded communities. They are involved in the topic of harm reduction in risky sex on stimulants (chemsex).
In the case of hepatitis C, for which they regularly test their clients and work with hepatologists in the event of a reactive test result and always advise clients of their treatment options in the event of laboratory confirmation of positivity. In 2024, they were able to conduct 2610 tests, of which 737 were for HCV. In case of a reactive result, clients were counselled and referred to a hepatologist for further testing.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close